Tag:

pancreatic cancer

Latest Headlines

Latest Headlines

Aduro nabs FDA 'breakthrough' nod for pancreatic cancer vaccine combo

Aduro BioTech's GVAX, a previously failed cancer vaccine, is finding new life in a combination treatment that the Berkeley-based company is testing in patients with pancreatic cancer.

J&J partner Aduro grabs an FDA 'breakthrough' nod for its immuno-oncology combo

Aduro BioTech joined the short list companies outside Big Pharma to pick up the FDA's coveted breakthrough therapy designation, impressing the agency with strong mid-stage results for its combo cancer therapy.

Nanoliposome vehicles bring second-wave treatment for metastatic pancreatic cancer

Patients with pancreatic cancer whose disease still persists after regular treatments may benefit from a new cancer drug nanoliposome formulation, according to a presentation at the European Society for Molecular Oncology's 16th World Congress on Gastrointestinal Cancer.

Halozyme soars after the FDA backs off of its cancer study

Halozyme is back on track with a midstage trial of its in-development pancreatic cancer treatment after the FDA lifted its clinical hold on enrollment, news that sent the company's shares up as much as 20%.

Texas team zeroes in on biomarker panel with earlier pancreatic cancer diagnosis in mind

Are you healthy? Do you have pancreatic cancer, pancreatitis or pancreatic cysts? In early testing, Texas researchers successfully used four blood biomarkers that aided in early-stage diagnosis to help tell the difference.

FDA drops a hold on Halozyme study

The latest news sliced only 3% off the biotech's share price.

Halozyme tanks after another mid-stage setback dings its cancer drug

Halozyme has pressed pause on a Phase II trial of its lead cancer candidate over safety concerns, news that sent the biotech's shares down 25% on Friday morning.

Northwest Bio, NewLink proceed with cancer vax trials to mixed reviews

A pair of biotechs will proceed with cancer vaccine studies thanks to recent recommendations from data-monitoring committees. Their announcements drew mixed results from investors, with Northwest Biotherapeutics' shares soaring and NewLink Genetics' sinking. But as they forge ahead, both companies will have to shake off the looming specters of failed cancer vaccine trials past.

NewLink's cancer vaccine brings hopeful investors back down to earth

After an interim analysis, NewLink Genetics is planning to keep on keeping on with a Phase III study of its cancer vaccine. But that news came as an apparent disappointment to investors, who hoped the drug's promise would result in an early trial termination, and the biotech's shares fell more than 12% on Friday morning.

CytomX 'probody' kills pancreatic cancer cells, leaves healthy tissue intact

Startup CytomX has unveiled new preclinical data showing that its fast-working antibody was effective in pancreatic cancer models as both a single agent and in combination with a currently approved cancer drug.